Lv31
250 积分 2022-08-02 加入
Comprehensive assessment of the causal effects and metabolite mediators of glucose-lowering drug targets on cardio-renal-liver-metabolic health
6小时前
已完结
Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
21天前
已关闭
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
1个月前
已完结
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
1个月前
已完结
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
1个月前
已完结
非内分泌科高血糖患者分布特点及相关危险因素分析
3个月前
已完结
司美格鲁肽片单药对比安慰剂治疗生活方式干预不佳中国2型糖尿病患者的有效性及安全性：PIONEER-11研究亚组分析
5个月前
已关闭
Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese Adults
6个月前
已完结
Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis
7个月前
已完结
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
7个月前
已完结
皖公网安备34019202002308
